Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ4200MR)

This product GTTS-WQ4200MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_000417.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3559
UniProt ID	P01589

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4200MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ12683MR	IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	OMP-21M18
GTTS-WQ14180MR	IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	REGN-910
GTTS-WQ3886MR	IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BCD-100
GTTS-WQ414MR	IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	2xCon4C
GTTS-WQ14951MR	IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	SHR-1210
GTTS-WQ4403MR	IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	BMS-663513
GTTS-WQ2850MR	IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AMG-570
GTTS-WQ11641MR	IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MGD-013

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST